Clinical development of Modified Vaccinia virus Ankara vaccines

Vaccine

Volumn 31, Issue 39, 2013, Pages 4241-4246

  Gilbert, Sarah C ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Clinical safety; Efficacy; Immunogenicity; Poxvirus; Vaccine

Indexed keywords

APICAL MEMBRANE ANTIGEN 1; CIRCUMSPOROZOITE PROTEIN; DNA VACCINE; MALARIA VACCINE; MODIFIED VACCINIA VIRUS ANKARA VACCINE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VACCINIA VACCINE;

ANTIGEN PRESENTATION; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DNA IMMUNIZATION; DRUG SCREENING; GENE GUN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SIMIAN VIRUS; T LYMPHOCYTE ACTIVATION; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INHIBITION; VIRUS REPLICATION;

CLINICAL SAFETY; EFFICACY; IMMUNOGENICITY; POXVIRUS; VACCINE;

ANIMALS; GENETIC VECTORS; HUMANS; MALARIA; SMALLPOX; SMALLPOX VACCINE; VACCINATION; VACCINES, ATTENUATED; VACCINIA VIRUS; VIRAL VACCINES;

EID: 84882816956     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.03.020     Document Type: Article

References (62)

1. Fenner F. The global eradication of smallpox. Med J Aust 1980, 1(10):455-465.
2. Gubser C., Hue S., Kellam P., Smith G.L. Poxvirus genomes: a phylogenetic analysis. J Gen Virol 2004, 85(Pt 1):105-117.
3. Kennedy R.B., Ovsyannikova I., Poland G.A. Smallpox vaccines for biodefense. Vaccine 2009, 27(Suppl 4):D73-D79.
4. Gordon S.N., Cecchinato V., Andresen V., Heraud J.M., Hryniewicz A., Parks R.W., et al. Smallpox vaccine safety is dependent on T cells and not B cells. J Infect Dis 2011, 203(8):1043-1053.
5. Mayr A., Stickl H., Muller H.K., Danner K., Singer H. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl). Zentralbl Bakteriol B 1978, 167(5,6):375-390. Erste Abteilung Originale.
6. Meisinger-Henschel C., Schmidt M., Lukassen S., Linke B., Krause L., Konietzny S., et al. Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara. J Gen Virol 2007, 88(Pt 12):3249-3259.
7. Meyer H., Sutter G., Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 1991, 72(Pt 5):1031-1038.
8. Blanchard T.J., Alcami A., Andrea P., Smith G.L. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J Gen Virol 1998, 79(Pt 5):1159-1167.
9. Carroll M.W., Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 1997, 238(2):198-211.
10. Meisinger-Henschel C., Spath M., Lukassen S., Wolferstatter M., Kachelriess H., Baur K., et al. Introduction of the six major genomic deletions of modified vaccinia virus Ankara (MVA) into the parental vaccinia virus is not sufficient to reproduce an MVA-like phenotype in cell culture and in mice. J Virol 2010, 84(19):9907-9919.
11. Stittelaar K.J., Kuiken T., de Swart R.L., van Amerongen G., Vos H.W., Niesters H.G., et al. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 2001, 19(27):3700-3709.
12. Sutter G., Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA 1992, 89(22):10847-10851.
13. Moss B., Carroll M.W., Wyatt L.S., Bennink J.R., Hirsch V.M., Goldstein S., et al. Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv Exp Med Biol 1996, 397:7-13.
14. Allsopp C.E., Plebanski M., Gilbert S., Sinden R.E., Harris S., Frankel G., et al. Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization. Eur J Immunol 1996, 26(8):1951-1959.
15. Gilbert S.C., Plebanski M., Harris S.J., Allsopp C.E., Thomas R., Layton G.T., et al. A protein particle vaccine containing multiple malaria epitopes. Nat Biotechnol 1997, 15(12):1280-1284.
16. Plebanski M., Gilbert S.C., Schneider J., Hannan C.M., Layton G., Blanchard T., et al. Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use. Eur J Immunol 1998, 28(12):4345-4355.
17. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 1998, 4(4):397-402.
18. Gilbert S.C., Schneider J., Plebanski M., Hannan C.M., Blanchard T.J., Smith G.L., et al. Ty virus-like particles: DNA vaccines and modified vaccinia virus Ankara; comparisons and combinations. Biol Chem 1999, 380(3):299-303.
19. + T cell immunogenicity and protective efficacy in the influenza and malaria models. Vaccine 1999, 18(7,8):623-632.
20. Schneider J., Langermans J.A., Gilbert S.C., Blanchard T.J., Twigg S., Naitza S., et al. A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees. Vaccine 2001, 19(32):4595-4602.
21. + T cells using heterologous prime-boost immunisation strategies. Immunol Rev 1999, 170:29-38.
22. Moorthy V.S., McConkey S., Roberts M., Gothard P., Arulanantham N., Degano P., et al. Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 2003, 21(17,18):2004-2011.
23. McConkey S.J., Reece W.H., Moorthy V.S., Webster D., Dunachie S., Butcher G., et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 2003, 9(6):729-735.
24. Moorthy V.S., Pinder M., Reece W.H., Watkins K., Atabani S., Hannan C., et al. Safety and immunogenicity of DNA/modified vaccinia virus Ankara malaria vaccination in African adults. J Infect Dis 2003, 188(8):1239-1244.
25. Moorthy V.S., Imoukhuede E.B., Milligan P., Bojang K., Keating S., Kaye P., et al. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med 2004, 1(2):e33.
26. + T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus. J Immunol 2004, 172(5):3094-3100.
27. Webster D.P., Dunachie S., Vuola J.M., Berthoud T., Keating S., Laidlaw S.M., et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci U S A 2005, 102(13):4836-4841.
28. Keating S.M., Bejon P., Berthoud T., Vuola J.M., Todryk S., Webster D.P., et al. Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J Immunol 2005, 175(9):5675-5680.
29. Bejon P., Peshu N., Gilbert S.C., Lowe B.S., Molyneux C.S., Forsdyke J., et al. Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens: ME-TRAP or the circumsporozoite protein, in children and adults in Kenya. Clin Infect Dis 2006, 42(8):1102-1110.
30. Bejon P., Mwacharo J., Kai O.K., Todryk S., Keating S., Lang T., et al. Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area. Vaccine 2006, 24(22):4709-4715.
31. Bejon P., Mwacharo J., Kai O., Mwangi T., Milligan P., Todryk S., et al. A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS Clin Trials 2006, 1(6):e29.
32. Bejon P., Mwacharo J., Kai O., Todryk S., Keating S., Lowe B., et al. The induction and persistence of T cell IFN-gamma responses after vaccination or natural exposure is suppressed by Plasmodium falciparum. J Immunol 2007, 179(6):4193-4201.
33. Gilbert S.C., Schneider J., Hannan C.M., Hu J.T., Plebanski M., Sinden R., et al. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine 2002, 20(7,8):1039-1045.
34. Mast T.C., Kierstead L., Gupta S.B., Nikas A.A., Kallas E.G., Novitsky V., et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 2010, 28(4):950-957.
35. Colloca S., Barnes E., Folgori A., Ammendola V., Capone S., Cirillo A., et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 2012, 4(115):115ra2.
36. Dicks M.D., Spencer A.J., Edwards N.J., Wadell G., Bojang K., Gilbert S.C., et al. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS ONE 2012, 7(7):e40385.
37. O'Hara G.A., Duncan C.J., Ewer K.J., Collins K.A., Elias S.C., Halstead F.D., et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis 2012, 205(5):772-781.
38. Sheehy S.H., Duncan C.J., Elias S.C., Collins K.A., Ewer K.J., Spencer A.J., et al. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther 2011, 19(12):2269-2276.
39. Sheehy S.H., Duncan C.J., Elias S.C., Biswas S., Collins K.A., O'Hara G.A., et al. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS ONE 2012, 7(2):e31208.
40. Gilbert S.C. T-cell-inducing vaccines - what's the future. Immunology 2012, 135(1):19-26.
41. McShane H., Pathan A.A., Sander C.R., Keating S.M., Gilbert S.C., Huygen K., et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004, 10(11):1240-1244.
42. Verreck F.A., Vervenne R.A., Kondova I., van Kralingen K.W., Remarque E.J., Braskamp G., et al. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS ONE 2009, 4(4):e5264.
43. Vordermeier H.M., Villarreal-Ramos B., Cockle P.J., McAulay M., Rhodes S.G., Thacker T., et al. Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Infect Immun 2009, 77(8):3364-3373.
44. Nicol M.P., Grobler L.A. MVA-85A, a novel candidate booster vaccine for the prevention of tuberculosis in children and adults. Curr Opin Mol Ther 2010, 12(1):124-134.
45. + T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine: MVA-NP+ M1. Clin Infect Dis 2011, 52(1):1-7.
46. Lillie P.J., Berthoud T.K., Powell T.J., Lambe T., Mullarkey C., Spencer A.J., et al. A preliminary assessment of the efficacy of a T cell-based influenza vaccine, MVA-NP+ M1, in humans. Clin Infect Dis 2012.
47. Guimaraes-Walker A., Mackie N., McCormack S., Hanke T., Schmidt C., Gilmour J., et al. Lessons from IAVI-006 a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers. Vaccine 2008, 26(51):6671-6677.
48. Garcia F., Bernaldo de Quiros J.C., Gomez C.E., Perdiguero B., Najera J.L., Jimenez V., et al. Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: a phase I clinical trial (RISVAC02). Vaccine 2011, 29(46):8309-8316.
49. Howles S., Guimaraes-Walker A., Yang H., Hancock G., di Gleria K., Tarragona-Fiol T., et al. Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects. Vaccine 2010, 28(45):7306-7312.
50. Bakari M., Aboud S., Nilsson C., Francis J., Buma D., Moshiro C., et al. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine 2011, 29(46):8417-8428.
51. Sandstrom E., Nilsson C., Hejdeman B., Brave A., Bratt G., Robb M., et al. Broad immunogenicity of a multigene: multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis 2008, 198(10):1482-1490.
52. Corona Gutierrez C.M., Tinoco A., Navarro T., Contreras M.L., Cortes R.R., Calzado P., et al. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1: CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther 2004, 15(5):421-431.
53. Garcia-Hernandez E., Gonzalez-Sanchez J.L., Andrade-Manzano A., Contreras M.L., Padilla S., Guzman C.C., et al. Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther 2006, 13(6):592-597.
54. Albarran Y.C.A., de la Garza A., Cruz Quiroz B.J., Vazquez Zea E., Diaz Estrada I., Mendez Fuentez E., et al. MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I/II study. BioDrugs 2007, 21(1):47-59.
55. Ma B., Xu Y., Hung C., Wu T. HPV and therapeutic vaccines where are we in 2010?. Curr Cancer Ther Rev 2010, 6:81-103.
56. Smith C.L., Mirza F., Pasquetto V., Tscharke D.C., Palmowski M.J., Dunbar P.R., et al. Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara. J Immunol 2005, 175(12):8431-8437.
57. Goepfert P.A., Elizaga M.L., Sato A., Qin L., Cardinali M., Hay C.M., et al. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis 2011, 203(5):610-619.
58. + T cell dependent and antibody mediated. Cancer Immunol Immunother 2006, 55(9):1081-1090.
59. Amato R.J., Stepankiw M. Clinical efficacy of TroVax in the treatment of progressive castration-resistant prostate cancer. Clinical medicine insights. Oncology 2012, 6:67-73.
60. Amato R.J., Hawkins R.E., Kaufman H.L., Thompson J.A., Tomczak P., Szczylik C., et al. Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res 2010, 16(22):5539-5547.
61. Harrop R., Treasure P., de Belin J., Kelleher M., Bolton G., Naylor S., et al. Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (TroVax). Cancer Immunol Immunother 2012, CII.
62. Orubu T., Alharbi N.K., Lambe T., Gilbert S.C., Cottingham M.G. Expression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA. PLoS ONE 2012, 7(6):e40167.